Analysts set Bio-Techne target price at $72.77 with a moderate buy consensus.

Bio-Techne Corp (NASDAQ:TECH) has received a consensus rating of "Moderate Buy" from 15 analysts, with an average target price of $72.77. The company recently reported quarterly earnings that beat expectations, with EPS of $0.46 and revenue of $295.88 million. Despite a slight year-over-year revenue decline, Bio-Techne declared a quarterly dividend and saw increased institutional investment. Analysts remain optimistic about the stock's growth potential, supported by strong fundamentals and positive analyst upgrades.